Norinnova Invest AS

Norinnova Invest AS is a Norwegian venture capital firm established in 2007, focusing on early-stage investments in technology and life sciences sectors. The firm primarily invests in seed and early venture phases, targeting growth companies with national and international ambitions. Norinnova Invest contributes capital, expertise, and networks, actively participating through board work to support the development of its portfolio companies.

The firm's investment strategy emphasizes technology and research-based growth companies in Northern Norway, particularly in areas where the region's research and development environment possesses strong national and international competence. Norinnova Invest collaborates with local research institutions and innovation companies to identify and support promising startups. The firm aims to create value by leveraging its expertise and networks to enhance the growth potential of its portfolio companies.

Norinnova Invest has a history of successful investments, including its involvement in Lytix Biopharma AS, a company focused on developing new cancer treatments. The firm has also achieved significant exits, such as the sale of its stake in Dualog AS in October 2023, marking one of its largest exits to date. These milestones reflect Norinnova Invest's commitment to fostering innovation and supporting the growth of high-tech companies in Northern Norway.